Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 39,495,708
  • Shares Outstanding, K 106,080
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.34
  • Price/Sales 8.12
  • Price/Cash Flow 37.03
  • Price/Book 8.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
363.39 +2.46%
on 04/18/17
401.21 -7.20%
on 03/29/17
-0.68 (-0.18%)
since 03/24/17
3-Month
340.96 +9.20%
on 01/27/17
401.21 -7.20%
on 03/29/17
+31.57 (+9.26%)
since 01/26/17
52-Week
325.35 +14.44%
on 11/04/16
452.96 -17.80%
on 11/14/16
-34.34 (-8.44%)
since 04/26/16

Most Recent Stories

More News
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

CELG : 126.16 (+0.51%)
VRTX : 117.10 (-0.14%)
BMRN : 95.31 (+1.19%)
GILD : 67.78 (+0.98%)
REGN : 373.64 (+0.35%)
AMGN : 165.14 (+0.27%)
BIIB : 283.68 (-1.12%)
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA)...

SAN : 6.52 (-1.36%)
REGN : 373.64 (+0.35%)
SNY : 46.33 (-0.15%)
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly...

SAN : 6.52 (-1.36%)
REGN : 373.64 (+0.35%)
SNY : 46.33 (-0.15%)
Regeneron Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.24%

Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $363.39 to a high of $374.72. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day...

REGN : 373.64 (+0.35%)
Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2017 financial and operating results on Thursday, May 4, 2017, before the U.S. financial markets open....

REGN : 373.64 (+0.35%)
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

AZN : 30.55 (+0.20%)
ALNY : 53.00 (+3.21%)
REGN : 373.64 (+0.35%)
SNY : 46.33 (-0.15%)
Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma

Upcoming AWS Coverage on Regeneron Pharmaceuticals

ITEK : 2.05 (+3.54%)
REGN : 373.64 (+0.35%)
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

CELG : 126.16 (+0.51%)
VRTX : 117.10 (-0.14%)
OMED : 3.95 (+1.02%)
INCY : 124.90 (+0.41%)
GERN : 2.54 (-0.39%)
GILD : 67.78 (+0.98%)
REGN : 373.64 (+0.35%)
After Yesterday's Decline of 1.60%, Regeneron Pharmaceuticals Offers Investors Better Value

Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $374.00 to a high of $382.89. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day...

REGN : 373.64 (+0.35%)
Regeneron's Evinacumab Gets Breakthrough Therapy by FDA

Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia....

HSKA : 108.35 (+0.72%)
MDCO : 48.56 (-1.12%)
ALNY : 53.00 (+3.21%)
REGN : 373.64 (+0.35%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 379.09
1st Resistance Point 375.71
Last Price 373.64
1st Support Level 369.47
2nd Support Level 366.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.